| 5.63 0.6 (11.93%) | 01-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.64 |
1-year : | 7.76 |
| Resists | First : | 5.69 |
Second : | 6.64 |
| Pivot price | 4.81 |
|||
| Supports | First : | 4.89 |
Second : | 4.4 |
| MAs | MA(5) : | 5.02 |
MA(20) : | 4.8 |
| MA(100) : | 5.02 |
MA(250) : | 7.33  |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 82.2 |
D(3) : | 72.9 |
| RSI | RSI(14): 67 |
|||
| 52-week | High : | 19.48 | Low : | 4.15 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ECOR ] has closed above the upper band by 23.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 6.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.7 - 5.72 | 5.72 - 5.74 |
| Low: | 5 - 5.02 | 5.02 - 5.04 |
| Close: | 5.59 - 5.63 | 5.63 - 5.66 |
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Fri, 09 Jan 2026
electroCore, Inc.'s (NASDAQ:ECOR) Price Is Right But Growth Is Lacking - simplywall.st
Wed, 24 Dec 2025
Analysts Expect Breakeven For electroCore, Inc. (NASDAQ:ECOR) Before Long - Yahoo Finance
Wed, 03 Dec 2025
electrocore (ECOR) CEO Goldberger buys $4,840 in shares - Investing.com
Sun, 09 Nov 2025
electroCore, Inc. (NASDAQ:ECOR): When Will It Breakeven? - simplywall.st
Wed, 05 Nov 2025
electroCore, Inc. (ECOR) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance
Wed, 29 Oct 2025
Analysts Estimate electroCore, Inc. (ECOR) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 8 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 35.7 (%) |
| Held by Institutions | 8.9 (%) |
| Shares Short | 262 (K) |
| Shares Short P.Month | 279 (K) |
| EPS | -1.72 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.15 |
| Profit Margin | -47.5 % |
| Operating Margin | -33.2 % |
| Return on Assets (ttm) | -39.2 % |
| Return on Equity (ttm) | -337.9 % |
| Qtrly Rev. Growth | 32.5 % |
| Gross Profit (p.s.) | 3.2 |
| Sales Per Share | 3.73 |
| EBITDA (p.s.) | -1.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -3.3 |
| PEG Ratio | 0 |
| Price to Book value | -40.22 |
| Price to Sales | 1.5 |
| Price to Cash Flow | -5.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|